{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:04:44Z","timestamp":1777417484088,"version":"3.51.4"},"reference-count":11,"publisher":"SAGE Publications","issue":"7-8","license":[{"start":{"date-parts":[[1996,7,1]],"date-time":"1996-07-01T00:00:00Z","timestamp":836179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[1996,7]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To report two cases of hypertension related to amphotericin B infusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CASE SUMMARY:<\/jats:title>\n                    <jats:p>A 63-year-old woman with Candida albicans bacteremia and an 84-year-old man with Aspergillus fumigatus pneumonia developed hypertension within minutes of amphotericin B administration. Both patients' blood pressure returned to baseline soon after the infusion of amphotericin B was stopped. Neither patient was rechallenged.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION:<\/jats:title>\n                    <jats:p>A causal relationship may exist between the administration of amphotericin B and these hypertensive episodes. Blood pressure in both patients normalized without treatment on discontinuation of the infusion. The mechanism of amphotericin B-associated hypertension is unclear but could include vasoconstricting properties of the drug or the administration of intravenous NaCl 0.9% prior to amphotericin B infusion. We recommend that intravenous NaCl 0.9% be administered following amphotericin B infusion and that the infusion be stopped if hypertensive episodes arise.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Both acute hypertension and hypotension can occur in patients receiving amphotericin B for systemic fungal infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJETIVO:<\/jats:title>\n                    <jats:p>Reportar dos casos de hipertensi\u00f3n relacionados a la infusi\u00f3n de anfotericina B.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESUMEN DEL CASO:<\/jats:title>\n                    <jats:p>Una paciente de 63 a\u00f1os de edad con bacteremia debida a la Candida albicans y un paciente de 84 a\u00f1os de edad con neumon\u00eda debida al Aspergillus fumigatus desarrollaron hipertensi\u00f3n a los pocos minutos de comenzar la administraci\u00f3n de anfotericina B. La presi\u00f3n sangu\u00ednea de ambos pacientes retorn\u00f3 a la l\u00ednea de base tan pronto como se detuvo la infusi\u00f3n de anfortericina B. Ninguno de los dos pacientes fue reexpuesto a la anfotericina B para determinar si el evento se repeat\u00eda.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSI\u00d3N:<\/jats:title>\n                    <jats:p>Puede existir una relaci\u00f3n causal entre la adminstraci\u00f3n de anfotericina B y estos episodios de hipertensi\u00f3n reportados, ya que la presi\u00f3n sangu\u00ednea se normaliz\u00f3 en ambos pacientes sin necesidad de tratamiento adicional despu\u00e9s de que se suspendi\u00f3 la infusi\u00f3n de anfotericina B. El mecanismo por el cual anfotericina est\u00e1 asociada al desarrollo de hipertensi\u00f3n no est\u00e1 claro pero se especula que se debe a las propiedades vasoconstrictoras del medicamento o a la administraci\u00f3n de cloruro de sodio intravenosamente antes de comenzar la infusi\u00f3n de anfotericina B. Por consiguiente, los autores recomiendan que el cloruro de sodio sea administrado despu\u00e9s de que se haya concluido la infusi\u00f3n de anfotericina B. En el caso de que se reporten episodios hipertensivos, la infusi\u00f3n de anfotericina B deber\u00eda ser suspendida inmediatamente.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONES:<\/jats:title>\n                    <jats:p>Casos de hipertensi\u00f3n o hipotensi\u00f3n pueden ocurrir en pacientes que reciben anfotericina B para el tratamiento de infecciones fungosas sist\u00e9micas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/106002809603000711","type":"journal-article","created":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T07:41:20Z","timestamp":1483688480000},"page":"765-767","source":"Crossref","is-referenced-by-count":17,"title":["Amphotericin B-Associated Hypertension"],"prefix":"10.1177","volume":"30","author":[{"given":"Ysa","family":"Le","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khurram Z","family":"Rana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael N","family":"Dudley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1996,7,1]]},"reference":[{"key":"bibr1-106002809603000711","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.2.308"},{"key":"bibr2-106002809603000711","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/33.2.203"},{"key":"bibr3-106002809603000711","first-page":"1156","volume":"49","author":"Kintzel PE","year":"1992","journal-title":"Am J Hosp Pharm"},{"key":"bibr4-106002809603000711","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/161.3.588"},{"key":"bibr5-106002809603000711","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/17.4.817"},{"key":"bibr6-106002809603000711","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(92)90039-E"},{"key":"bibr7-106002809603000711","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199409000-00027"},{"key":"bibr8-106002809603000711","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.11.2542"},{"key":"bibr9-106002809603000711","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.27.5.868"},{"key":"bibr10-106002809603000711","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.7.1402"},{"key":"bibr11-106002809603000711","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115240"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/106002809603000711","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/106002809603000711","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:04:56Z","timestamp":1777374296000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/106002809603000711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,7]]},"references-count":11,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[1996,7]]}},"alternative-id":["10.1177\/106002809603000711"],"URL":"https:\/\/doi.org\/10.1177\/106002809603000711","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,7]]}}}